Cytotoxic activities, cellular uptake, gene regulation, and optical imaging of novel platinum(II) complexes

Chemical Research in Toxicology

Volumn 22, Issue 10, 2009, Pages 1705-1712

  Gao, Jian ^a,b   Liu, Ya Guang ^b   Zingaro, Ralph A ^a  

^a TEXAS A AND M UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLIN D1; CYCLOHEXANE; DIAMINOCYCLOHEXANE; MESSENGER RNA; OXALIPLATIN; PLATINUM COMPLEX; PLATINUM DERIVATIVE; PROTEIN BNIP3; PROTEIN P53; SULFORHODAMINE B; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; CELL STRAIN MCF 7; COLONY FORMATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; GENE CONTROL; HUMAN; HUMAN CELL; IN VITRO STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYNTHESIS;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; CYCLIN D1; DNA; FLUORESCENT DYES; GENE EXPRESSION REGULATION; HUMANS; MICROSCOPY, CONFOCAL; ORGANOPLATINUM COMPOUNDS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 70350237024     PISSN: 0893228X     EISSN: 15205010     Source Type: Journal    
DOI: 10.1021/tx900180v     Document Type: Article

References (20)

1. Rosenberg, B., Vancamp, L., and Krigas, T. (1965) Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 205, 698-699.
2. Prestayko, A. W., DiAoust, J. C., Issell, B. F., and Crooke, S. T. (1979) Cisplatin (cis-diamminedichloroplatinum (II). Cancer Treat. Rev. 6, 13-39.
3. Knox, R. J., Friedlos, F., and Lydall, D. A. (1986) Mechanism of cytotoxicity of anticancer platinum drugs: Evidence that cis- diamminedichloroplatinum( II) and cis-diammine-(1,1′- cyclobutanedicarboxylato) platinum(II) differ only in th kinetic of their interaction with DNA. Cancer Res. 46, 1972-1979. (Pubitemid 16080411)
4. Graham, J., Mushin, M., and Kirkpatrick, P. (2004) Oxaliplatin. Nat. Rev. Drug Discovery 3, 11-12.
5. Pasetto, L. M., Dandrea, M. R., Rossi, E., and Monfardini, S. (2006) Oxaliplatin-related neurotoxicity: How and why? Crit. Rev. Oncol. Hematol. 59, 159-168. (Pubitemid 44094106)
6. Monti, E., Gariboldi, M., Maiocchi, A., Marengo, E., Cassino, C., Gabano, E., and Osella, D. (2005) Cytotoxicity of cis-platinum(II) conjugate models: The effect of chelating arms and leaving groups on cytotoxicity: A quantitative structure-activity relationship approach. J. Med. Chem. 48, 857-866. (Pubitemid 40209108)
7. Berger, I., Nazarov, A. A., Hartinger, C. G., Groessl, M., Valiahdi, S. M., Jakupec, M. A., and Keppler, B. K. (2007) A glucose derivative as natural alternative to the cyclohexane-1,2-diamine ligand in the anticancer drug oxaliplatin? ChemMedChem 2, 505-514.
8. Bitha, P., Child, R. G., River, P., Hlavka, J. J., and Lin, Y. I. U. S. Patent Number 4,866,092, 1989.
9. Gao, J., Liu, Y., Zhou, Y., and Zingaro, R. A. (2007) Chiral salicyl diamines: potent anticancer molecules. ChemMedChem 2, 1723.
10. Woynarowski, J. M., Chapman, W. G., Napier, C., Herzig, M. C. S., and Juniewicz, P. (1998) Sequence and region-specificity of oxaloplatin adducts in naked and cellular DNA. Mol. Pharmacol. 54, 770-777. (Pubitemid 28523169)
11. Mandal, R., Sawyer, M. B., and Li, X. (2006) Mass spectrometry study of hemoglobin-oxaliplatin complexes in colorectal cancer patients and potential association with chemotherapeutic responses. Rapid Commun. Mass Spectrom. 0, 2533-2538. (Pubitemid 44320206)
12. Bose, R. N., Maurmann, L., Mishur, R. J., Yasui, L., Gupta, S., Grayburn, W. S., Hofstetter, H., and Salley, T. (2008) Non-DNA-binding platinum anticancer agents: cytotoxic activities of platinum-phosphato complexes towards human ovarian cancer cells. Proc. Natl. Acad. Sci. U.S.A. 105, 18314-18319.
13. Hah, S. S., Sumbad, R. A., White, R. W., Turteltaub, K. W., and Henderson, P. T. (2009) Characterization of oxaliplatin-DNA adduct formation in DNA and differentiation of cancer cell drug sensitivity at microdose concentration. Chem. Res. Toxicol. 20, 1745-1751.
14. Criado, J. J., Fernandez, E. R., Manzano, J. L., Alonso, A., Barrena, S., Medarde, M., Pelaez, R., Tabero, M. D., and Orfao, A. (2005) Intrisically fluorescent cytotoxic cisplatin analogues as DNA marker molecules. Bioconjugate Chem. 16, 275-282. (Pubitemid 40388202)
15. Gao, J., Woolley, F. R., and Zingaro, R. A. (2005) In vitro anticancer activities and optical imaging of novel intercalative non-cisplatin conjugates. J. Med. Chem. 48, 7192-7197. (Pubitemid 41743632)
16. Perez-Andres, M., Benito, J. J., Rodriguez-Fernandez, E., Corradetti, B., Primo, D., Manzano, J. L., Orfao, A., and Criado, J. J. (2008) Bisursodeoxycholate(ethylenediamine)platinum(II): A new autofluorescent compound. Cytotoxic activity and cell cycle analysis in ovarian and hematological cell lines. Dalton Trans. 28, 6159-6164.
17. Malon, M., Travnicel, Z., R, Marek, R., and Strnad, M. (2005) Synthesis, spectral study and cytotoxicity of platinum(II) complexes with 2,9-disubstituted-6-benzylaminopurines. J. Inorg. Biochem. 99, 2127-2138. (Pubitemid 41562855)
18. Amundson, S. A., Myers, T. G., Scudiero, D., Kitada, S., Reed, J. C., and Formace, A. J., Jr. (2000) An informatics approach identifying makers of chemosensitivity in human cancer cell lines. Cancer Res. 60, 6101-6110.
19. Reed, J. C. (1999) Mechanism of apoptosis avoidance in cancer. Curr. Opin. Oncol. 11, 68-75.
20. Raymond, E., Faivre, S., Chaney, S., Woynarowski, J., and Cvitkovic, E. (2002) Cellular and molecular pharmacology of oxaliplatin. Mol. Cancer Ther. 1, 227-235.